Literature DB >> 23172968

Comment on: Vila et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-2596.

Jens Jordan, Andreas L Birkenfeld.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23172968      PMCID: PMC3501864          DOI: 10.2337/db12-1061

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


× No keyword cloud information.
Vila et al. (1) reported that brain natriuretic peptide (BNP) infusions reduce total and acylated-ghrelin levels while increasing satiety. Since ghrelin acts orexigenic, the authors conclude that BNP might indirectly regulate food intake in conditions associated with excessive BNP levels, such as in heart failure. The hypothesis is provocative but ignores the complex metabolic actions of natriuretic peptides. Because ghrelin stimulates hypothalamic AMP-activated protein kinase (AMPK) activity, reduced ghrelin promotes satiety, attenuating food intake. However, other factors could be involved as well. Insulin, glucose, and specific fatty acids inhibit central AMPK activity, also promoting satiety. Atrial natriuretic peptide and BNP potently stimulate human adipose tissue lipolysis (2–4). Resulting fatty acid release is associated with increased circulating insulin concentrations (5–7). Furthermore, natriuretic peptides induce lipid oxidation and energy expenditure in mice (8,9) and men (5). Increased hepatic lipid oxidation generates β-hydroxybutyrate (5), which also affects food intake. Thus, natriuretic peptides affect several important mechanisms involved in the regulation of food intake independently of ghrelin. Moreover, natriuretic peptide–induced changes in insulin could indirectly regulate ghrelin (10). Besides, the hypothesis that BNP has a crucial role in the regulation of food intake is challenged by observations in mice transgenically overexpressing BNP. These animals show chronically elevated BNP plasma concentrations comparable to levels attained with BNP infusions in clinical studies. Yet, feeding behavior and food intake are completely normal (8). Therefore, it is premature to conclude that natriuretic peptides regulate satiety and food intake through ghrelin. Integrative human studies are required that take into account the wide spectrum of metabolic actions elicited by natriuretic peptides.
  10 in total

1.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

2.  Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls.

Authors:  Jan Polak; Martin Kotrc; Zuzana Wedellova; Antonin Jabor; Ivan Malek; Josef Kautzner; Ludmila Kazdova; Vojtech Melenovsky
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

3.  Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation.

Authors:  Andreas L Birkenfeld; Michael Boschmann; Cedric Moro; Frauke Adams; Karsten Heusser; Jens Tank; André Diedrich; Christoph Schroeder; Gabi Franke; Michel Berlan; Friedrich C Luft; Max Lafontan; Jens Jordan
Journal:  J Clin Endocrinol Metab       Date:  2006-09-19       Impact factor: 5.958

4.  Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans.

Authors:  Andreas L Birkenfeld; Michael Boschmann; Cedric Moro; Frauke Adams; Karsten Heusser; Gabriele Franke; Michel Berlan; Friedrich C Luft; Max Lafontan; Jens Jordan
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

5.  Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans.

Authors:  M Möhlig; J Spranger; B Otto; M Ristow; M Tschöp; A F H Pfeiffer
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 6.  Control of lipolysis by natriuretic peptides and cyclic GMP.

Authors:  Max Lafontan; Cédric Moro; Michel Berlan; François Crampes; Coralie Sengenes; Jean Galitzky
Journal:  Trends Endocrinol Metab       Date:  2008-03-11       Impact factor: 12.015

7.  Increase in circulating insulin induced by atrial natriuretic peptide in normal humans.

Authors:  D E Uehlinger; P Weidmann; M P Gnädinger; L Hasler; C Bachmann; S Shaw; B Hellmüller; R E Lang
Journal:  J Cardiovasc Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.105

8.  B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men.

Authors:  Greisa Vila; Gabriele Grimm; Michael Resl; Birgit Heinisch; Elisa Einwallner; Harald Esterbauer; Benjamin Dieplinger; Thomas Mueller; Anton Luger; Martin Clodi
Journal:  Diabetes       Date:  2012-06-14       Impact factor: 9.461

9.  Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity.

Authors:  Kazutoshi Miyashita; Hiroshi Itoh; Hirokazu Tsujimoto; Naohisa Tamura; Yasutomo Fukunaga; Masakatsu Sone; Kenichi Yamahara; Daisuke Taura; Megumi Inuzuka; Takuhiro Sonoyama; Kazuwa Nakao
Journal:  Diabetes       Date:  2009-08-18       Impact factor: 9.461

10.  Atrial natriuretic peptide induces postprandial lipid oxidation in humans.

Authors:  Andreas L Birkenfeld; Petra Budziarek; Michael Boschmann; Cedric Moro; Frauke Adams; Gabriele Franke; Michel Berlan; Marie A Marques; Fred C G J Sweep; Friedrich C Luft; Max Lafontan; Jens Jordan
Journal:  Diabetes       Date:  2008-10-03       Impact factor: 9.461

  10 in total
  1 in total

Review 1.  Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk.

Authors:  Riccardo Sarzani; Francesco Spannella; Federico Giulietti; Paolo Balietti; Guido Cocci; Marica Bordicchia
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.